Compare JUBILANT LIFE SCIENCES with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES DR. DATSONS LABS JUBILANT LIFE SCIENCES/
DR. DATSONS LABS
 
P/E (TTM) x 15.7 -10.9 - View Chart
P/BV x 1.8 0.2 1,079.8% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   DR. DATSONS LABS
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
DR. DATSONS LABS
Mar-14
JUBILANT LIFE SCIENCES/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs898126 715.0%   
Low Rs61831 1,998.4%   
Sales per share (Unadj.) Rs572.0133.0 430.1%  
Earnings per share (Unadj.) Rs36.20.2 23,894.2%  
Cash flow per share (Unadj.) Rs59.56.6 900.6%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.9128.8 234.4%  
Shares outstanding (eoy) m159.2831.66 503.1%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x1.30.6 225.1%   
Avg P/E ratio x20.9516.1 4.1%  
P/CF ratio (eoy) x12.711.8 107.5%  
Price / Book Value ratio x2.50.6 413.1%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,6942,477 4,871.8%   
No. of employees `0002.4NA-   
Total wages/salary Rs m19,26056 34,392.1%   
Avg. sales/employee Rs Th38,120.6NM-  
Avg. wages/employee Rs Th8,058.4NM-  
Avg. net profit/employee Rs Th2,414.3NM-  
INCOME DATA
Net Sales Rs m91,1084,211 2,163.8%  
Other income Rs m35779 454.1%   
Total revenues Rs m91,4664,289 2,132.5%   
Gross profit Rs m17,390569 3,058.4%  
Depreciation Rs m3,709204 1,814.6%   
Interest Rs m2,198430 510.9%   
Profit before tax Rs m11,84013 93,231.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,2686 53,573.8%   
Profit after tax Rs m5,7705 120,210.4%  
Gross profit margin %19.113.5 141.3%  
Effective tax rate %27.648.0 57.5%   
Net profit margin %6.30.1 5,555.4%  
BALANCE SHEET DATA
Current assets Rs m45,8486,852 669.2%   
Current liabilities Rs m20,8976,711 311.4%   
Net working cap to sales %27.43.3 817.8%  
Current ratio x2.21.0 214.9%  
Inventory Days Days57161 35.3%  
Debtors Days Days51318 16.0%  
Net fixed assets Rs m65,4983,673 1,783.2%   
Share capital Rs m159317 50.3%   
"Free" reserves Rs m47,9303,761 1,274.4%   
Net worth Rs m48,0894,078 1,179.4%   
Long term debt Rs m42,4291,671 2,539.4%   
Total assets Rs m114,68512,633 907.9%  
Interest coverage x6.41.0 620.4%   
Debt to equity ratio x0.90.4 215.3%  
Sales to assets ratio x0.80.3 238.3%   
Return on assets %6.93.4 201.8%  
Return on equity %12.00.1 10,192.7%  
Return on capital %12.47.7 161.8%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m12,422964 1,288.6%   
Fx outflow Rs m17,227607 2,837.6%   
Net fx Rs m-4,805357 -1,346.3%   
CASH FLOW
From Operations Rs m11,2151,345 834.0%  
From Investments Rs m-10,118-2,256 448.6%  
From Financial Activity Rs m6,574-1,200 -547.9%  
Net Cashflow Rs m7,612-2,111 -360.6%  

Share Holding

Indian Promoters % 45.6 4.5 1,006.6%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 0.0 -  
FIIs % 21.2 1.4 1,570.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 94.1 22.4%  
Shareholders   23,815 20,807 114.5%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  FULFORD INDIA  DR. REDDYS LAB  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Lower; Tata Steel & Maruti Suzuki Top Losers(12:30 pm)

Share markets in India are presently trading on a negative note, tracking a selloff in global equities amid rising concerns over Chinese coronavirus epidemic.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Feb 24, 2020 02:17 PM

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - VENUS REMEDIES COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS